HEИндивидуална стипендия2025–2027

NEUROGLIOSOLVE · RNA biology and neuroglial function: resolving the cellular and subcellular transcriptome in myotonic dystrophy brains, towards new brain gene therapy

„Хоризонт Европа“ — Действия „Мария Склодовска-Кюри“

Период
2025-04-01 → 2027-03-31
Финансиране от ЕС
195 915 €
Участници
2
Схема
HORIZON-TMA-MSCA-PF-EF

Линиите свързват координатора с партньорите.

Накратко на български

Молекулярните процеси в мозъка при миотонична дистрофия тип 1 се анализират чрез проучване на взаимодействието между неврони и астроцити. Разбирането на тези механизми помага за разработването на нови методи за генна терапия при когнитивни и поведенчески нарушения.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Цел на проекта

RNA biology is critical for the molecular orchestration of the interplay between specialized brain cell types, and disrupted RNA processing, can cause human disease. A prime example is Myotonic Dystrophy type 1(DM1), a multisystemic disorder caused by the expansion of a non-coding trinucleotide DNA repeat and that involves cognitive impairment and behavioral changes. Molecular pathogenesis is driven by the nuclear accumulation of RNA foci, which sequester RNA-binding proteins that regulate splicing, polyadenylation and subcellular localization of downstream transcripts. However, we do not know the cell populations, molecular pathways and cell-cell interactions primarily affected in the brain. A critical question to develop effective molecular therapies. My host laboratory developed a unique mouse model of DM1 that mirrors the spatiotemporal expression of toxic RNA and relevant brain phenotypes. Using these mice, I will fill three knowledge gaps:(1) I will employ advanced spatial transcriptomics to unravel the vulnerability of diverse cell types throughout brain development and aging;(2) I will use the TRAP technology to uncover subcellular transcriptomic abnormalities in specialized neuron-astrocyte contacts and identify pivotal disease intermediates of neuroglial miscommunication;(3) I will use my expertise in AAV-mediated brain gene delivery to test the capacity of engineered protein decoys, developed in my host laboratory, to release the RNA-binding proteins sequestered in brain cells and correct the behavioral, molecular neurobiological deficit in DM1 mice. Through the integration of cutting-edge transcriptomics with a new focus on synaptic neuroglial communication, I will elucidate DM1 brain pathogenesis with unprecedented spatiotemporal resolution, and offer a framework to understand other conditions mediated by toxic RNA repeats, for which DM1 serves as a paradigm. Simultaneously, my project will enhance our understanding of RNA biology in the brain.

Оригинален текст от CORDIS (на английски).

Участници

  • INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE · ParisКоординаторФранция
  • SORBONNE UNIVERSITE · ParisФранция

Връзки

Данни: CORDIS, © Европейски съюз